Lundbeck gains selected Asian rights to Teva's Parkinson's drug
This article was originally published in Scrip
Executive Summary
Lundbeck has acquired rights in six Asian markets to Teva Pharmaceutical Industries' Parkinson's disease therapy Azilect (rasagiline).